{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T15:15:29Z","timestamp":1769008529509,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,10,8]],"date-time":"2016-10-08T00:00:00Z","timestamp":1475884800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s12185-016-2098-8","type":"journal-article","created":{"date-parts":[[2016,10,8]],"date-time":"2016-10-08T06:58:04Z","timestamp":1475909884000},"page":"644-646","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Minimal incidence of neurotoxicity without prophylaxis during busulfan-based conditioning regimen in patients undergoing stem cell transplantation"],"prefix":"10.1007","volume":"104","author":[{"given":"Eucario","family":"Leon-Rodriguez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica M.","family":"Rivera-Franco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,10,8]]},"reference":[{"issue":"6753","key":"2098_CR1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0140-6736(53)90884-8","volume":"264","author":"A Haddow","year":"1953","unstructured":"Haddow A, Timmis GM. Myleran in chronic myeloid leukemia. Chemical constitution and biological action. Lancet. 1953;264(6753):207\u20138.","journal-title":"Lancet"},{"issue":"5","key":"2098_CR2","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.bbmt.2008.12.489","volume":"15","author":"SO Ciurea","year":"2009","unstructured":"Ciurea SO, Andersson BS. Busulfan\u00a0in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15(5):523\u201336.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2098_CR3","first-page":"1781","volume":"53","author":"GW Santos","year":"1974","unstructured":"Santos GW, Tutschka PJ. Marrow transplantation in the busulfan-treated rat: preclinical model of aplastic anemia. J Natl Cancer Inst. 1974;53:1781\u20135.","journal-title":"J Natl Cancer Inst"},{"key":"2098_CR4","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198312013092202","volume":"309","author":"GW Santos","year":"1983","unstructured":"Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med. 1983;309:1347\u201353.","journal-title":"N Engl J Med"},{"issue":"4","key":"2098_CR5","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood.V49.4.511.511","volume":"49","author":"ED Thomas","year":"1977","unstructured":"Thomas ED, Buckner CD, Banaji M, Clift RA, Fefer A, Flournoy N. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood. 1977;49(4):511\u201333.","journal-title":"Blood"},{"key":"2098_CR6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1182\/blood.V45.2.171.171","volume":"45","author":"AW Bleyer","year":"1975","unstructured":"Bleyer AW, Blaese RM, Bujak JS, Herzig GP, Graw RG. Long-term remission from acute myelogenous leukemia after bone marrow transplantation and recovery from acute graft-versus-host reaction and prolonged immunoincompetence. Blood. 1975;45:171\u201381.","journal-title":"Blood"},{"issue":"5","key":"2098_CR7","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood.V70.5.1382.1382","volume":"70","author":"PJ Tutschka","year":"1987","unstructured":"Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood. 1987;70(5):1382\u20138.","journal-title":"Blood"},{"issue":"3","key":"2098_CR8","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood.V78.3.838.838","volume":"78","author":"EA Copelan","year":"1991","unstructured":"Copelan EA, Biggs JC, Thompson JM, Crilley P, Szer J, Klein JP. Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2. Blood. 1991;78(3):838\u201343.","journal-title":"Blood"},{"issue":"1","key":"2098_CR9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2174\/157488608783333899","volume":"3","author":"N Krivoy","year":"2008","unstructured":"Krivoy N, Hoffer E, Lurie Y, Bentur Y, Rowe JM. Busulfan\u00a0use in hematopoietic stem cell transplantation: pharmacology, dose adjustment, safety and efficacy in adults and children. Curr Drug Saf. 2008;3(1):60\u20136.","journal-title":"Curr Drug Saf"},{"issue":"Suppl 1","key":"2098_CR10","first-page":"236","volume":"4","author":"GW Santos","year":"1989","unstructured":"Santos GW. Busulfan (Bu) and cyclophosphamide (Cy) for marrow transplantation. Bone Marrow Transplant. 1989;4(Suppl 1):236\u20139.","journal-title":"Bone Marrow Transplant"},{"issue":"5A","key":"2098_CR11","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S1083-8791(00)70064-4","volume":"6","author":"BS Andersson","year":"2000","unstructured":"Andersson BS, Madden T, Tran HT, Hu WW, Blume KG, Chow DS. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplant conditioning therapy: a phase I study. Biol Blood Marrow Transplant. 2000;6(5A):548\u201354.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2098_CR12","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s002800050404","volume":"37","author":"HP Bhagwatwar","year":"1996","unstructured":"Bhagwatwar HP, Phadungpojna S, Chow DS, Andersson BS. Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy. Cancer Chemother Pharmacol. 1996;37(5):401\u201340.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"2098_CR13","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood.V85.11.3005.bloodjournal85113005","volume":"85","author":"SI Bearman","year":"1995","unstructured":"Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood. 1995;85(11):3005\u201320.","journal-title":"Blood"},{"key":"2098_CR14","unstructured":"Grochow LB. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol. 1993;20(4 Suppl 4):18\u201325 (quiz 26)."},{"issue":"19","key":"2098_CR15","first-page":"6203","volume":"50","author":"G Vassal","year":"1990","unstructured":"Vassal G, Deroussent A, Hartmann O, Challine D, Benhamou E, Valteau-Couanet D. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res. 1990;50(19):6203\u20137.","journal-title":"Cancer Res"},{"issue":"8417\u20138418","key":"2098_CR16","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/S0140-6736(84)91649-0","volume":"2","author":"RE Marcus","year":"1984","unstructured":"Marcus RE, Goldman JM. Convulsions due to high-dose busulphan. Lancet. 1984;2(8417\u20138418):1463.","journal-title":"Lancet"},{"issue":"6","key":"2098_CR17","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/BF00257448","volume":"24","author":"G Vassal","year":"1989","unstructured":"Vassal G, Gouyette A, Hartmann O, Pico JL, Lemerle J. Pharmacokinetics of high-dose busulfan in children. Cancer Chemother Pharmacol. 1989;24(6):386\u201390.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"2098_CR18","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/BF00558081","volume":"36","author":"M Hassan","year":"1989","unstructured":"Hassan M, Oberg G, Ehrsson H, Ehrnebo M, Wallin I, Smedmyr B. Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol. 1989;36(5):525\u201330.","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"2098_CR19","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1592\/phco.28.12.1502","volume":"28","author":"AL Eberly","year":"2008","unstructured":"Eberly AL, Anderson GD, Bubalo JS, McCune JS. Optimal prevention of seizures induced by high-dose\u00a0busulfan. Pharmacotherapy. 2008;28(12):1502\u201310.","journal-title":"Pharmacotherapy"},{"issue":"12","key":"2098_CR20","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/sj.bmt.1703593","volume":"29","author":"KW Chan","year":"2002","unstructured":"Chan KW, Mullen CA, Worth LL, Choroszy M, Koontz S, Tran H. Lorazepam for seizure prophylaxis during high-dose busulfan administration. Bone Marrow Transplant. 2002;29(12):963\u20135.","journal-title":"Bone Marrow Transplant"},{"key":"2098_CR21","doi-asserted-by":"crossref","unstructured":"Floeter AE, McCune JS. Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients. J Oncol Pharm Pract. 2016 (Epub ahead of print).","DOI":"10.1177\/1078155216651128"},{"issue":"3","key":"2098_CR22","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s11096-013-9768-x","volume":"35","author":"MS Diaz-Carrasco","year":"2013","unstructured":"Diaz-Carrasco MS, Olmos R, Blanquer M, Velasco J, S\u00e1nchez-Salinas A, Moraleda JM. Clonazepam for seizure prophylaxis in adult \/patients treated with high dose\u00a0busulfan. Int J Clin Pharm. 2013;35(3):339\u201343.","journal-title":"Int J Clin Pharm."},{"issue":"7","key":"2098_CR23","first-page":"2977","volume":"30","author":"E Carreras","year":"2010","unstructured":"Carreras E, Cahn JY, Puozzo C, Kr\u00f6ger N, Sanz G, Buzyn A. Influence on Busilvex pharmacokinetics of clonazepam compared to previous phenytoin historical data. Anticancer Res. 2010;30(7):2977\u201384.","journal-title":"Anticancer Res"},{"issue":"3","key":"2098_CR24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF00686213","volume":"33","author":"M Hassan","year":"1993","unstructured":"Hassan M, Oberg G, Bj\u00f6rkholm M, Wallin I, Lindgren M. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol. 1993;33(3):181\u20136.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"2098_CR25","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/oxfordjournals.annonc.a058131","volume":"3","author":"G Meloni","year":"1992","unstructured":"Meloni G, Raucci U, Pinto RM, Spalice A, Vignetti M, Iannetti P. Pretrasplant conditioning with busulfan and cyclophosphamide in acute leukemia patients: neurological and electroencephalographic prospective study. Ann Oncol. 1992;3(2):145\u20138.","journal-title":"Ann Oncol"},{"issue":"1","key":"2098_CR26","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/106002809202600107","volume":"26","author":"CP Murphy","year":"1992","unstructured":"Murphy CP, Harden EA, Thompson JM. Generalized seizures secondary to high-dose busulfan therapy. Ann Pharmacother. 1992;26(1):30\u20131.","journal-title":"Ann Pharmacother"},{"issue":"12","key":"2098_CR27","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1200\/JCO.1986.4.12.1804","volume":"4","author":"O Hartmann","year":"1986","unstructured":"Hartmann O, Benhamou E, Beaujean F, Pico JL, Kalifa C, Patte C. High-dose busulfan and cyclophosphamide with autologous bone marrow transplantation support in advanced malignancies in children: a phase II study. J Clin Oncol. 1986;4(12):1804\u201310.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2098_CR28","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/sj.bmt.1701076","volume":"21","author":"R Kobayashi","year":"1998","unstructured":"Kobayashi R, Watanabe N, Iguchi A, Cho Y, Yoshida M, Arioka H. Electroencephalogram abnormality and high-dose busulfan in conditioning regimens for stem cell transplantation. Bone Marrow Transplant. 1998;21(3):217\u201320.","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2098_CR29","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10072-004-0237-0","volume":"25","author":"C Morgia La","year":"2004","unstructured":"La Morgia C, Mondini S, Guarino M, Bonifazi F, Cirignotta F. Busulfan neurotoxicity and EEG abnormalities: a case report. Neurol Sci. 2004;25(2):95\u20137.","journal-title":"Neurol Sci"},{"issue":"5","key":"2098_CR30","first-page":"363","volume":"7","author":"R Camara De La","year":"1991","unstructured":"De La Camara R, Tomas JF, Figuera A, Berberana M, Fernandez-Ra\u00f1ada JM. High dose busulfan and seizures. Bone Marrow Transplant. 1991;7(5):363\u20134.","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2098_CR31","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.bbmt.2013.10.028","volume":"20","author":"D Caselli","year":"2014","unstructured":"Caselli D, Rosati A, Faraci M, Podda M, Ripaldi M, Longoni D. Risk of seizures in children receiving busulphan-containing regimens for stem cell transplantation. Biol Blood Marrow Transplant. 2014;20(2):282\u20135.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2098_CR32","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/ajh.23270","volume":"87","author":"GJ Ruiz-Arg\u00fcelles","year":"2012","unstructured":"Ruiz-Arg\u00fcelles GJ, Gomez-Almaguer D, Steensma DP. Outdated dogma? Busulfan, seizure prophylaxis, and stem cell allografting. Am J Hematol. 2012;87(9):941.","journal-title":"Am J Hematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-016-2098-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-016-2098-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-016-2098-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T13:53:06Z","timestamp":1601128386000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-016-2098-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,8]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2098"],"URL":"https:\/\/doi.org\/10.1007\/s12185-016-2098-8","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,8]]}}}